TECHNOLOGY

LIPOSHELL®

Proprietary, patented liposomal technology called LIPOSHELL® enables encapsulation of substances with unprecedented efficiency, resulting in their rapid and enhanced delivery to desired places in the body. Different compounds like RNAs, peptides, conventional APIs, contrast agents or nutrients, both water soluble and non-soluble can be encapsulated.

Due to the similarity to natural cell membranes in the body, LIPOSHELL® nanocarriers are characterized by high structural stability enabling long-lasting and stable encapsulation of active substances in their interior. LIPOSHELL® liposomes are the highest quality nano-carriers, with precisely controlled size distribution and phys-chem properties.

With LIPOSHELL® nano-carriers one can achieve:

• increase in bioavailability of transported substances,
• protection of transported substances to avoid their degradation,
• optimization of dosage;
• increase in therapy effectiveness
• minimalization of systemic or local toxicity.

LIPOSHELL® nano-carriers can be used as effective, advanced drug carriers, with properties specifically tailored to meet the intended purpose. The versatility of liposomal carriers results from the unique structural properties.

LIPOSHELL® patent family

Applications of state-of-the-art
LIPOSHELL® nano-formulations

ORAL DELIVERY

LIPOSHELL® nano-carriers due to their tailor-made structure enable the oral delivery of active substances via two independent transport routes, namely:

  • • blood circulation system (standard absorption route);
  • • lymphatic system (alternative route).

This alterna’ve transport route based on transendocythosis is available only for nanoformula’ons, characterized with precisely controlled phys-chem parameters such as size distribu’on and high encapsula’on-efficacy to name a few. LIPOSHELL® based formula’onsfor oral delivery provide this advantage along with cargo protec’on in stomach, resul’ng in higher absorp’on rates along with the reduced stomach-related side effects

TOPICAL

LIPOSHELL® nano-carriers due to the amphiphilic nature of their components (phospholipids) and high-encapsulation rates can facilitate effective transport of hydrophilic compounds into the skin as well as trans-dermally.

OPHTALMIC

Flexibility of LIPOSHELL® based nano-carriers in terms of structural and surface properties enables to design a nano-carrier which will deliver its cargo to the specific eye compartment. LIPOSHELL® carriers can effectively be used for treatment of DES related malfunctions of tear-film layer, corneal as well as retinal delivery.

IV

LIPOSHELL® based nano-carriers enable effective delivery of their cargo when administrated parenterally. Drug cumulation in the therapeutic area can be achieved via the passive diffusion (i.e. tumor targeting) as well as active targeting due to the surface modifications introduced in the carrier (i.e. via surface grafted ligands). In addition, systemic toxicity of some drugs can be greatly reduced due to their targeted delivery (low systemic exposure, i.e. cytostatics).

SERVICES

  • • Formulation development
  • • GMP up-scaling with small batch manufacturing
  • • GMP analytical services
  • • GMP manufacturing – batches for clinical trials

SONOSOME®

SONOSOME® are liposomal drug nano-carriers, which have high contrast for high frequency ultrasounds. This
contrast is a result of specific composition of the membrane as well as mechanical properties of the intravesicle aqueous phase. Such design of the liposome allows for the controlled release of the liposome content
locally in the body where the ultrasound beam is focused (High Intensity Focused Ultrasound HIFU).

Data shows the correlation between absorbed energy by liposome suspension and the stability of lipid
membrane. The destabilization of the lipid membrane leads to the release of the pharmacologically active
ingredient.

This design also elevate its sensibility to mechanical stimulus lowering the chance for the destruction of the
surrounding tissues. In comparison to currently established methodologies it can be further developed into
broader therapeutic applications, not limited to anticancer only.

TOP PAPERS

1. Przybylo M., Sýkora J., Humpolickova J., Benda A., Zan A., & Hof M. (2006). Lipid diffusion in giant unilamellar vesicles is more than 2 times faster than in supported phospholipid bilayers under identical conditions. Langmuir, 22(22), 9096-9099.
https://pubs.acs.org/doi/abs/10.1021/la061934p

2. Lis M., Wizert A., Przybylo M., Langner M., Swiatek J., Jungwirth P., & Cwiklik L. (2011). The effect of lipid oxidation on the water permeability of phospholipids bilayers. Physical Chemistry Chemical Physics, 13(39), 17555-17563.
https://pubs.rsc.org/en/content/articlelanding/2011/cp/c1cp21009b/unauth

3. Hui S. W., Langner M., Zhao Y. L., Ross P., Hurley E. & Chan K. (1996). The role of helper lipids in cationic liposome-mediated gene transfer. Biophysical journal, 71(2), 590-599.
https://www.sciencedirect.com/science/article/pii/S0006349596793098

4. Langner M. & Kubica K. (1999). The electrostatics of lipid surfaces. Chemistry and physics of lipids, 101(1), 3-35.
https://www.sciencedirect.com/science/article/abs/pii/S0009308499000523

5. Byström R., Aisenbrey C., Borowik T., Bokvist M., Lindström F., Sani, M. A., Olofsson A. & Gröbner G. (2008). Disordered proteins: biological membranes as two-dimensional aggregation matrices. Cell biochemistry and biophysics, 52, 175-189.
https://link.springer.com/article/10.1007/s12013-008-9033-4

6. Łukawski M., Dałek P., Borowik T., Foryś A., Langner M., Witkiewicz W. & Przybyło M. (2020). New oral liposomal vitamin C formulation: Properties and bioavailability. Journal of liposome research, 30(3), 227-234.
https://www.tandfonline.com/doi/abs/10.1080/08982104.2019.1630642

Lipid Systems Sp. z o.o.
Krzemieniecka 48C
54-613 Wrocław
phone: (+48) 730 052 571
e-mail: office@lipid-systems.pl

KRS 0000395576
REGON 021636530
VAT ID (NIP) 8943032420

WEBSITE TERMS AND CONDITIONS

PRIVACY POLICY